JP6034888B2 - Novel statin intermediate and method for producing pitavastatin, rosuvastatin, cerivastatin and fluvastatin using the same - Google Patents
Novel statin intermediate and method for producing pitavastatin, rosuvastatin, cerivastatin and fluvastatin using the same Download PDFInfo
- Publication number
- JP6034888B2 JP6034888B2 JP2014560870A JP2014560870A JP6034888B2 JP 6034888 B2 JP6034888 B2 JP 6034888B2 JP 2014560870 A JP2014560870 A JP 2014560870A JP 2014560870 A JP2014560870 A JP 2014560870A JP 6034888 B2 JP6034888 B2 JP 6034888B2
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- alkyl
- following general
- aralkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 20
- 229960002797 pitavastatin Drugs 0.000 title claims description 13
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 title claims description 11
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 title claims description 10
- 229960005110 cerivastatin Drugs 0.000 title claims description 10
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title claims description 10
- 229960000672 rosuvastatin Drugs 0.000 title claims description 10
- 229960003765 fluvastatin Drugs 0.000 title description 8
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- -1 Arginyl halide Chemical class 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000003747 Grignard reaction Methods 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 8
- 150000004795 grignard reagents Chemical class 0.000 claims description 6
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 claims description 6
- 239000007818 Grignard reagent Substances 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 claims description 4
- 238000007239 Wittig reaction Methods 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000003377 acid catalyst Substances 0.000 claims description 2
- 150000004820 halides Chemical group 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 1
- 239000001639 calcium acetate Substances 0.000 claims 1
- 229960005147 calcium acetate Drugs 0.000 claims 1
- 235000011092 calcium acetate Nutrition 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- CHEYRYWZYKYUHU-CCEZHUSRSA-N tert-butyl (e)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-5-hydroxy-3-oxohept-6-enoate Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\C(O)CC(=O)CC(=O)OC(C)(C)C)=C1C1=CC=C(F)C=C1 CHEYRYWZYKYUHU-CCEZHUSRSA-N 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000000543 intermediate Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 150000002009 diols Chemical group 0.000 description 9
- 238000010511 deprotection reaction Methods 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 7
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical class OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
- HBWDWGMBZIFBQE-UHFFFAOYSA-N benzylboronic acid Chemical compound OB(O)CC1=CC=CC=C1 HBWDWGMBZIFBQE-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000002978 peroxides Chemical class 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 150000001543 aryl boronic acids Chemical class 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001502 aryl halides Chemical class 0.000 description 3
- 229960005370 atorvastatin Drugs 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 0 CC(C)c1c(C=C[C@]2OB(CC3=C*(C)=CC4=C=C34)O[C@@](CC(O*)=O)C2)c(C(C=C2)=C(C)C(**C3)C=C2F)c3c(N(C)C)n1 Chemical compound CC(C)c1c(C=C[C@]2OB(CC3=C*(C)=CC4=C=C34)O[C@@](CC(O*)=O)C2)c(C(C=C2)=C(C)C(**C3)C=C2F)c3c(N(C)C)n1 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- HZQLUIZFUXNFHK-UHFFFAOYSA-N 1-(bromomethyl)-4-phenylbenzene Chemical group C1=CC(CBr)=CC=C1C1=CC=CC=C1 HZQLUIZFUXNFHK-UHFFFAOYSA-N 0.000 description 1
- RUHJZSZTSCSTCC-UHFFFAOYSA-N 2-(bromomethyl)naphthalene Chemical compound C1=CC=CC2=CC(CBr)=CC=C21 RUHJZSZTSCSTCC-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UFMHFXFYNDTOER-RJTITELWSA-N C(C)(C)(C)OC(C[C@@H](C[C@@H](COC1OCCCC1)O)O)=O Chemical compound C(C)(C)(C)OC(C[C@@H](C[C@@H](COC1OCCCC1)O)O)=O UFMHFXFYNDTOER-RJTITELWSA-N 0.000 description 1
- NKRCCZITHSKAEP-UHFFFAOYSA-M CC(C)N(C1=CC=CC=C11)C(C(C=CC=C2)=C2[P+](C)(C2=CC=CC=C2)C2=CC=CC=C2)=C1C(C=C1)=CC=C1F.[Br-] Chemical compound CC(C)N(C1=CC=CC=C11)C(C(C=CC=C2)=C2[P+](C)(C2=CC=CC=C2)C2=CC=CC=C2)=C1C(C=C1)=CC=C1F.[Br-] NKRCCZITHSKAEP-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- LGPSQXJVHWBACI-UHFFFAOYSA-M [2-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]phenyl]-methyl-diphenylphosphanium bromide Chemical compound [Br-].C1(CC1)C1=NC2=CC=CC=C2C(=C1C1=C(C=CC=C1)[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C)C1=CC=C(C=C1)F LGPSQXJVHWBACI-UHFFFAOYSA-M 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KOCXMMTWVKMODE-UHFFFAOYSA-N bromobenzene;phosphane Chemical compound P.BrC1=CC=CC=C1 KOCXMMTWVKMODE-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010502 deborylation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- VPRUMANMDWQMNF-UHFFFAOYSA-N phenylethane boronic acid Chemical compound OB(O)CCC1=CC=CC=C1 VPRUMANMDWQMNF-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
- C07C15/20—Polycyclic condensed hydrocarbons
- C07C15/27—Polycyclic condensed hydrocarbons containing three rings
- C07C15/28—Anthracenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
- C07C15/20—Polycyclic condensed hydrocarbons
- C07C15/24—Polycyclic condensed hydrocarbons containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、スタチン（ｓｔａｔｉｎ）類の合成に用いられる新規な中間体及びその製造方法、並びに上記スタチン類中間体を用いてピタバスタチン、ロスバスタチン、セリバスタチン、フルバスタチンを製造する方法に関する。 The present invention relates to a novel intermediate used for the synthesis of statins and a method for producing the same, and a method for producing pitavastatin, rosuvastatin, cerivastatin and fluvastatin using the above-mentioned statins intermediate.
ＨＭＧ−ＣｏＡ還元酵素（３−ｈｙｄｒｏｘｙ−３−ｍｅｔｈｙｌ−ｇｌｕｔａｒｙｌ Ｃｏｅｎｚｙｍｅ Ａ ｒｅｄｕｃｔａｓｅ）は、肝組織（ｌｉｖｅｒ ｔｉｓｓｕｅ）に存在することが知られており、血中コレステロール生成に重要な役割を果たす。このようなＨＭＧ−ＣｏＡ還元酵素の活性を抑制することによってコレステロールの生成を阻害する物質を一般に「スタチン（ｓｔａｔｉｎｓ）」と呼んでおり、スタチン類化合物の代表として、アトルバスタチン（Ａｔｏｒｖａｓｔａｔｉｎ）、ピタバスタチン（Ｐｉｔａｖａｓｔａｔｉｎ）、フルバスタチン（Ｆｌｕｖａｓｔａｔｉｎ）、ロスバスタチン（Ｒｏｓｕｖａｓｔａｔｉｎ）、セリバスタチン（Ｃｅｒｉｖａｓｔａｉｎ）などがよく知られている。 HMG-CoA reductase (3-hydroxy-3-methyl-Coenzyme A reductase) is known to exist in liver tissue and plays an important role in blood cholesterol production. Such a substance that inhibits the production of cholesterol by suppressing the activity of HMG-CoA reductase is generally called “statins”. Representative examples of statins are atorvastatin, pitavastatin, and pitavastatin. ), Fluvastatin, rosuvastatin, cerivastatin and the like are well known.
このようなスタチン類は、高脂血症、高コレステロール血症、高中性脂肪血症のような異常脂質血症（ｄｙｓｌｉｐｉｄｅｍｉａ）、又は心血管系疾患の治療剤として主に用いられている。ピタバスタチン、ロスバスタチン、セリバスタチン及びフルバスタチンの構造は下記一般式の通りであり、通常、ヘミカルシウム塩の剤形で市販されている。 Such statins are mainly used as therapeutic agents for hyperlipidemia, hypercholesterolemia, dyslipidemia such as hypertriglyceridemia, or cardiovascular diseases. The structures of pitavastatin, rosuvastatin, cerivastatin and fluvastatin are represented by the following general formula, and are usually marketed in the form of hemicalcium salt.
［ピタバスタチン］ [Pitavastatin]
［ロスバスタチン］ [Rosuvastatin]
［セリバスタチン］ [Cerivastatin]
［フルバスタチン］ [Fluvastatin]
上述したスタチン化合物は、それぞれの母核（芳香環）構造は異なっているが、同一のジヒドロキシ構造を有している。ピタバスタチンをはじめとする合成中間体については、既に多くの研究が行われてきており、ヨーロッパ特許ＥＰ００３０４０６３、ＥＰ０５２０４０６；米国特許ＵＳ５，３９９，７２２、ＵＳ５，９９８，６３３；国際公開特許ＷＯ２００２／６３０２８号、ＷＯ２００４／０７０７１７号などに関連技術内容が開示されている。 The above-mentioned statin compounds have the same dihydroxy structure, although each mother nucleus (aromatic ring) structure is different. Much research has already been conducted on synthetic intermediates including pitavastatin, including European Patents EP00304063, EP0520406; US Patents US5,399,722, US5,998,633; International Patent Publication WO2002 / 63028, The related technical contents are disclosed in WO2004 / 070717 and the like.
国際公開特許ＷＯ２００３／０７０７３３号は、アリールボロン酸を用いてエステル化合物のジヒドロキシ基（ジオール基）を保護した下記一般式の中間体について開示している。このような中間体は、アトルバスタチン、セリバスタチン、ロスバスタチンの合成に有用である。 International Publication No. WO2003 / 070733 discloses an intermediate of the following general formula in which an arylboronic acid is used to protect a dihydroxy group (diol group) of an ester compound. Such intermediates are useful for the synthesis of atorvastatin, cerivastatin, rosuvastatin.
（式中、Ａｒは、アリール又はヘテロアリールである。） (In the formula, Ar is aryl or heteroaryl.)
また、米国特許第６，８６７，３０６号は、アトルバスタチンを製造するための中間体として、上記の国際公開特許と類似のアリールボロン酸を用いてｔ−ブチル６−シアノ−３，５−ジヒドロキシヘキサノエートのジオール基（ｄｉｏｌ ｇｒｏｕｐ）を保護（ｐｒｏｔｅｃｔｉｎｇ）した下記一般式のボロネート化合物を記述している。 In addition, US Pat. No. 6,867,306 uses t-butyl 6-cyano-3,5-dihydroxyhexayl as an intermediate for producing atorvastatin by using an arylboronic acid similar to the above-mentioned international patent. Describes boronate compounds of the general formula: Protecting the diol group of noate.
（式中、Ｒは、水素、メチル、３-ニトロ基である。） (In the formula, R is hydrogen, methyl or 3-nitro group.)
上記の国際公開特許ＷＯ２００３／０７０７３３号及び米国特許第６，８６７，３０６号で用いられるフェニルボロン酸のようなアリールボロン酸は、一般に、アリールハライド（Ａｒ−Ｘ）とボロネート化合物をグリニャール反応（Ｇｒｉｇｎａｒｄ ｒｅａｃｔｉｏｎ）させて合成するが、フェニルハライドのようなアリールハライドは、グリニャール反応に必要な有機溶媒、すなわち、テトラヒドロフラン（ＴＨＦ）、ジエチルエステルなどに対して溶解度（ｓｏｌｕｂｉｌｉｔｙ）が低い。そのため、充分なグリニャール反応のためには過量の有機溶媒を使用しなければならないことから製造コストが高くなり、室温以下の温度でグリニャール試薬が析出する場合が度々あり、製造工程が難しいという問題がある。また、Ｄｅｎｎｉｓ Ｇ．Ｈａｌｌ（Ｂｏｒｏｎｉｃ Ａｃｉｄｓ，２００５ ＷＩＬＥＹ−ＶＣＨ Ｖｅｒｌａｇ ＧｍｂＨ ＆ Ｃｏ．ＫＧａＡ ｐｐ．２２）によれば、フェニルボロン酸をジオール保護基として用いる場合、脱保護反応である酸化的脱ホウ素化(Ｏｘｄａｔｉｖｅ ｄｅｂｏｒｏｎａｔｉｏｎ)（ペルオキシド（Ｐｅｒｏｘｉｄｅ）使用）を行わなくても、下記反応式のように、中性の溶液でも分解しやいため安定度が非常に低い。したがって、スタチン類の合成時に、フェニルボロン酸をジオール保護基として用いると、中間体の安定度が低いため、収率が低下するとともに、高純度の製品を生産し難いという短所がある。 Arylboronic acids such as phenylboronic acid used in the above-mentioned International Patent Publications WO2003 / 070733 and US Pat. No. 6,867,306 generally include aryl halide (Ar—X) and boronate compounds in Grignard reaction (Grignard reaction). The aryl halide such as phenyl halide has low solubility in an organic solvent necessary for the Grignard reaction, that is, tetrahydrofuran (THF), diethyl ester, and the like. Therefore, an excessive amount of an organic solvent must be used for a sufficient Grignard reaction, resulting in a high production cost. In many cases, Grignard reagents are precipitated at a temperature below room temperature, and the production process is difficult. is there. Dennis G. et al. According to Hall (Boronic Acids, 2005 WILEY-VCH Verlag GmbH & Co. KGaA pp. 22), when phenylboronic acid is used as a diol protecting group, oxidative deboration (peroxide deboronation) (peroxide Even if (Peroxide) is not used, the neutral solution is easily decomposed as shown in the following reaction formula, so the stability is very low. Therefore, when phenylboronic acid is used as a diol protecting group during the synthesis of statins, the stability of the intermediate is low, so that the yield is lowered and it is difficult to produce a high-purity product.
本発明は、スタチン類の製造に用いられる従来のボロネート化合物における上記の問題点を解消することのできる新規なスタチン中間体と、これらの中間体を用いてピタバスタチン、ロスバスタチン、セリバスタチン及びフルバスタチンを効果的に製造する方法を提供することにその目的がある。 The present invention is a novel statin intermediate capable of solving the above-mentioned problems in conventional boronate compounds used for the production of statins, and pitavastatin, rosuvastatin, cerivastatin and fluvastatin are effective using these intermediates. Its purpose is to provide a method of manufacturing in an automated manner.
上記目的を達成するために、本発明は、下記一般式１で表示される新規なスタチン中間体を提供する。 In order to achieve the above object, the present invention provides a novel statin intermediate represented by the following general formula 1.
［一般式１] [General Formula 1]
（式中、 (Where
ＲR １1 、Ｒ, R ２2 、Ｒ, R ３3 はそれぞれ独立して、Ｈ、ＣAre independently H, C １1 〜Ｃ~ C ４4 のアルキルであり、ＲOf alkyl and R ４4 はＣIs C １1 〜Ｃ~ C ８8 のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルである。）Alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl. )
本発明の上記ボロネート化合物は、芳香環（Ａｒｏｍａｔｉｃ ｒｉｎｇ）とボロン（Ｂ）との間に１個以上の炭素鎖（−ＣＨ２−）を有するため、グリニャール反応において有機溶媒に容易に溶解し、よって、量産時に有機溶媒量を減少させて製造コストを大幅に低減することができ、且つ、反応生成物が容易に結晶化する他、脱保護（ｄｅｐｒｏｔｅｃｔｉｎｇ）後に脱離するボロン酸も結晶性が非常に良いため、回収して再利用できるという長所がある。 Since the boronate compound of the present invention has one or more carbon chains (—CH 2 —) between an aromatic ring and boron (B), it is easily dissolved in an organic solvent in a Grignard reaction. Therefore, the production cost can be greatly reduced by reducing the amount of organic solvent during mass production, and the reaction product is easily crystallized, and the boronic acid released after deprotection is also crystalline. It is very good and has the advantage that it can be recovered and reused.
ただし、ベンジルボロン酸をジオール保護基として用いる場合、脱保護反応である酸化的脱ホウ素化（ペルオキシド使用）を行うとき、脱保護反応時間は２時間以内と迅速に終結するが、フェニルエチルボロン酸を用いてジオール保護をした場合は、同一条件下で脱保護反応時間が約１２時間以内と長くなるため、ベンジルボロン酸の場合に比べて不純物が少量増加する。 However, when benzylboronic acid is used as a diol protecting group, when oxidative deboration (using peroxide), which is a deprotection reaction, is carried out, the deprotection reaction time is rapidly terminated within 2 hours. When diol protection is carried out using, the deprotection reaction time is as long as about 12 hours or less under the same conditions, so that impurities are increased by a small amount compared to benzylboronic acid.
上記一般式１のボロネート化合物は、下記反応式１に示すように、（ａ）下記一般式６のアラルキルハライド（Ａｒａｌｋｙｌ ｈａｌｉｄｅ）をマグネシウムと反応させてグリニャール試薬を調製した後、トリメトキシボラン（ｔｒｉｍｅｔｈｏｘｙｂｏｒａｎ）とグリニャール反応（Ｇｒｉｇｎａｒｄ ｒｅａｃｔｉｏｎ）させて下記一般式５のアラルキルボロン酸（Ａｒａｌｋｙｌ ｂｏｒｏｎｉｃ ａｃｉｄ）を合成する段階；（ｂ）下記一般式５のアラルキルボロン酸を下記一般式４で表されるアセテート化合物と反応させて下記一般式３のボロネートエステル化合物を合成する段階；（ｃ）下記一般式３のボロネートエステル化合物を弱い酸触媒を用いて脱保護して下記一般式２の化合物を生成する段階；（ｄ）下記一般式２の化合物を塩化オキサリル又はクロロクロム酸ピリジニウムを用いて酸化させる段階を含んで高収率で製造することができる。 As shown in the following reaction formula 1, the boronate compound of the general formula 1 is prepared by reacting (a) an aralkyl halide of the following general formula 6 with magnesium to prepare a Grignard reagent, and then trimethoxyborane (trimethoxyborane). ) and Grignard reaction (Grignard reaction) is allowed to step to synthesize aralkyl boronic acid of the general formula 5 (aralkyl boronic acid); ( b) acetate compound aralkyl boronic acid of the general formula 5 is represented by the following general formula 4 to produce the compound of the following formula 2 is deprotected with (c) the following general formula 3 of boronate ester compound weak acid catalyst; reacted step of synthesizing boronate ester compound of the following formula 3 and stage; (d) compounds of the following general formula 2 Can be produced in high yield, including the step of oxidizing with oxalyl chloride or pyridinium chlorochromate.
［反応式１］ [Reaction Formula 1]
（式中、 (Where
Ｘは、Ｂｒ、Ｃｌ又はＩであり、 X is Br, Cl or I;
ＲR １1 、Ｒ, R ２2 、Ｒ, R ３3 はそれぞれ独立して、Ｈ、ＣAre independently H, C １1 〜Ｃ~ C ４4 のアルキルであり、The alkyl of
Ｒ ４ は、Ｃ１〜Ｃ８のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルであり、 R 4 is C 1 -C 8 alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl;
Ｒ ５ は、テトラヒドロピラニル、ｔ−ブチルジメチルシリル又はトリチルである。） R 5 is tetrahydropyranyl, t-butyldimethylsilyl or trityl. )
一方、本発明は、上記一般式１のボロネート化合物を用いて、下記一般式７乃至１０で表されるスタチン類合成中間体を提供する。 On the other hand, the present invention provides a statin synthesis intermediate represented by the following general formulas 7 to 10 using the boronate compound of the general formula 1.
［一般式７］ [General Formula 7]
［一般式８］ [General Formula 8]
［一般式９］ [General formula 9]
［一般式１０］ [General formula 10]
（式中、
Ｒ １ 、Ｒ ２ 、Ｒ ３ はそれぞれ独立して、Ｈ、Ｃ １ 〜Ｃ ４ のアルキルであり、Ｒ ４ はＣ １ 〜Ｃ ８ のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルである。）
(Where
R 1 , R 2 , R 3 are each independently H, C 1 -C 4 alkyl, and R 4 is C 1 -C 8 alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl. . )
本発明に係るスタチン中間体は、芳香環（Ａｒｏｍａｔｉｃ ｒｉｎｇ）とボロン（Ｂ）との間に１個以上の炭素鎖（−ＣＨ２−）を有するため、従来の炭素鎖を持たないアリールボロン酸に比べてＴＨＦ、ジエチルエステルなどの有機溶媒に容易に溶解し、よって、量産時に有機溶媒使用量を著しく減少させて製造コストを低減することができ、且つ、反応生成物が容易に結晶化する他、脱保護後に脱離するボロン酸も結晶性が非常に良いため、回収して再利用できるという長所がある。 Since the statin intermediate according to the present invention has one or more carbon chains (—CH 2 —) between an aromatic ring and boron (B), an aryl boronic acid having no conventional carbon chain Compared to the above, it can be easily dissolved in organic solvents such as THF and diethyl ester, so that the amount of organic solvent used can be significantly reduced during mass production to reduce the production cost, and the reaction product is easily crystallized. In addition, the boronic acid released after deprotection has the advantage that it can be recovered and reused because it has very good crystallinity.
本発明は、下記一般式１で表される新規なボロネート化合物を提供する。このボロネート化合物は、スタチンを製造するための中間体として用いられる。 The present invention provides a novel boronate compound represented by the following general formula 1. This boronate compound is used as an intermediate to produce statins.
［一般式１］ [General Formula 1]
（式中、 (Where
ＲR １1 、Ｒ, R ２2 、Ｒ, R ３3 はそれぞれ独立して、Ｈ、ＣAre independently H, C １1 〜Ｃ~ C ４4 のアルキルであり、ＲOf alkyl and R ４4 はＣIs C １1 〜Ｃ~ C ８8 のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルである。）Alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl. )
ベンジルボロン酸をジオール保護基として用いる場合、脱保護反応である酸化的脱ホウ素化（ペルオキシド使用）を行うとき、脱保護反応時間は２時間以内と迅速に終結するが、フェニルエチルボロン酸を用いてジオール保護をした場合は、同一条件下で脱保護反応時間が約１２時間以内と長くなるため、ベンジルボロン酸の場合に比べて不純物が少量増加する。 When benzylboronic acid is used as a diol protecting group, when oxidative deboration (using peroxide), which is a deprotection reaction, is performed, the deprotection reaction time is completed within 2 hours, but phenylethylboronic acid is used. In the case of diol protection, the deprotection reaction time becomes as long as about 12 hours or less under the same conditions, so that impurities are increased by a small amount compared to benzylboronic acid.
上記一般式１のスタチン中間体は、下記反応式１に示すように、一般式５のアラルキルボロン酸と一般式４の１，３−ジオール化合物をトルエン、キシレン、ジクロロメタン、四塩化炭素などの有機溶媒下で、９０℃〜１２０℃、１０〜１５時間程度反応させてジオール基をボロン（Ｂ）基で保護（ｐｒｏｔｅｃｔｉｎｇ）した後、Ｒ２基を脱離して脱保護した後、残っているヒドロキシ基を酸化させてアルデヒド化合物に転換する。 As shown in the following reaction formula 1, the statin intermediate of the above general formula 1 is an organic compound such as toluene, xylene, dichloromethane, carbon tetrachloride, etc. containing an aralkylboronic acid of the general formula 5 and a 1,3-diol compound of the general formula 4. After reacting in a solvent at 90 ° C. to 120 ° C. for about 10 to 15 hours to protect the diol group with a boron (B) group, the R 2 group is eliminated and deprotected, and then the remaining hydroxy The group is oxidized and converted to an aldehyde compound.
上記一般式５のアラルキルボロン酸は、一般式６のアラルキルハライドをテトラヒドロフラン（ＴＨＦ）、エチルエステルなどのような有機溶媒下にマグネシウム金属を処理してグリニャール試薬を調製した後、トリメトキシボラン（ｔｒｉｍｅｔｈｏｘｙｂｏｒａｎｅ）を徐々に滴加しながらグリニャール反応（Ｇｒｉｇｎａｒｄ ｒｅａｃｔｉｏｎ）させて合成する。 The aralkylboronic acid of the above general formula 5 is prepared by treating the aralkyl halide of the general formula 6 with a magnesium metal in an organic solvent such as tetrahydrofuran (THF), ethyl ester, etc. to prepare a Grignard reagent, and then trimethoxyborane (trimethoxyborane). ) Is gradually added dropwise to synthesize Grignard reaction.
［反応式１］ [Reaction Formula 1]
上記一般式４の１，３−ジオール化合物は、公知の方法で準備することができる。 The 1,3-diol compound of the general formula 4 can be prepared by a known method.
上記のようにして得た一般式１のボロネート化合物を、下記一般式７ａ乃至１０ａで表されるスタチンの母核（芳香環）と塩基存在下でウィッティヒ反応（ｗｉｔｔｉｇ ｒｅａｃｔｉｏｎ）させることによって、（Ｅ）−異性質体であるスタチンを高収率で得ることができ、その後、ボロン酸を脱保護することによって各種のスタチン化合物又はその塩を製造することが可能になる。 The boronate compound of the general formula 1 obtained as described above is subjected to a Wittig reaction in the presence of a base (aromatic ring) of a statin represented by the following general formulas 7a to 10a in the presence of a base (E ) -Statin that is an isomer can be obtained in high yield, and then various statin compounds or salts thereof can be produced by deprotecting the boronic acid.
［一般式７ａ］ [General Formula 7a]
［一般式８ａ］ [General Formula 8a]
［一般式９ａ］ [General Formula 9a]
［一般式１０ａ］ [General Formula 10a]
上記の一般式７ａ乃至１０ａにおいて、 In the above general formulas 7a to 10a,
Ｙは、ＰＰｈ３ ＋Ｘ−（Ｘ＝ハライド）又はＰ(Ｏ)(ＯＥｔ)２である。 Y is PPh 3 + X − (X = halide) or P (O) (OEt) 2 .
［一般式７］ [General Formula 7]
［一般式８］ [General Formula 8]
［一般式９］ [General formula 9]
［一般式１０］ [General formula 10]
（上記の一般式７乃至１０において、 (In the above general formulas 7 to 10,
Ｒ １ 、Ｒ ２ 、Ｒ ３ はそれぞれ独立して、Ｈ、Ｃ １ 〜Ｃ ４ のアルキルであり、Ｒ ４ はＣ １ 〜Ｃ ８ のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルである。） R 1 , R 2 , R 3 are each independently H, C 1 -C 4 alkyl, and R 4 is C 1 -C 8 alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl. . )
上記ウィッティヒ反応に用いられる塩基としては金属水和物、金属酸化物又は金属炭酸塩が好ましい。例えば、水酸化リチウム、水酸化リチウム水和物、水酸化ナトリウム、水酸化カリウム、カリウムｔ−ブトキシド及びナトリウムメトキシドから選ばれる１種以上が好ましい。使用される塩基の当量比は、出発物質である一般式７ａの化合物に対して１．０乃至５．０当量、好ましくは、１．５乃至３．０当量である。反応時間は２乃至１０時間程度が好ましい。 The base used for the Wittig reaction is preferably a metal hydrate, metal oxide or metal carbonate. For example, at least one selected from lithium hydroxide, lithium hydroxide hydrate, sodium hydroxide, potassium hydroxide, potassium t-butoxide and sodium methoxide is preferable. The equivalent ratio of the base used is 1.0 to 5.0 equivalents, preferably 1.5 to 3.0 equivalents, relative to the compound of the general formula 7a which is the starting material. The reaction time is preferably about 2 to 10 hours.
本発明の一般式７乃至１０の化合物の合成は、ジメチルスルホキシド（ＤＭＳＯ）、ジメチルホルムアミド、ジメチルアセトアミド、トルエン、アセトニトリル、テトラヒドロフラン（ＴＨＦ）、ジエチルエーテル、ジイソプロピルエーテルなどのようなエーテル溶媒、又は塩化メチレン（ＭＣ）、１，２−ジクロロエタン、クロロホルムなどのハロゲン化溶媒などのような有機溶媒で行うことができ、これらの溶媒は、単独又は混合溶媒として用いることができる。反応温度は、０℃乃至１５０℃の範囲が好適であり、３０℃乃至１００℃がより好ましい。 Synthesis of the compounds of the general formulas 7 to 10 of the present invention is carried out by using dimethyl sulfoxide (DMSO), dimethylformamide, dimethylacetamide, toluene, acetonitrile, tetrahydrofuran (THF), ether solvents such as diethyl ether, diisopropyl ether, etc., or methylene chloride. (MC), 1,2-dichloroethane, can be performed with an organic solvent such as a halogenated solvent such as chloroform, and these solvents can be used alone or as a mixed solvent. The reaction temperature is preferably in the range of 0 ° C. to 150 ° C., more preferably 30 ° C. to 100 ° C.
本発明の一般式７乃至１０の化合物の合成は、（Ｅ）−異性質体を選択的に極めて優勢に提供する（（Ｅ）タイプと（Ｚ）タイプの比率が９９：１モル比程度である）。したがって、簡単な再結晶法によって９９％以上の（Ｅ）−異性質体である一般式７乃至一般式９の化合物を得ることができる。再結晶に用いられる溶媒は、塩化メチル、酢酸エチル、イソプロピルアルコール、メタノール、ジエチルエーテル、スルホランなどの極性溶媒はもとより、ヘキサン、ペンタン、ヘプタンなどの非極性溶媒を含むことができ、これらの溶媒から１種以上を選択して混合溶媒として用いることができる。 The synthesis of the compounds of the general formulas 7 to 10 according to the present invention provides the (E) -isomer selectively and very predominantly (the ratio of the (E) type to the (Z) type is about 99: 1 molar ratio). is there). Therefore, 99% or more of the (E) -isomer compounds of formulas 7 to 9 can be obtained by a simple recrystallization method. Solvents used for recrystallization can include non-polar solvents such as hexane, pentane and heptane as well as polar solvents such as methyl chloride, ethyl acetate, isopropyl alcohol, methanol, diethyl ether and sulfolane. One or more types can be selected and used as a mixed solvent.
以下、実施例を用いて本発明を詳しく説明する。 Hereinafter, the present invention will be described in detail with reference to examples.
実施例１． ｔ−ブチル２−（（４Ｒ，６Ｓ）−２−ベンジル−６−ホルミル−１，３，２−ジオキサボリナン−４−イル）アセテートの合成：（一般式I）Example 1. Synthesis of t-butyl 2-((4R, 6S) -2-benzyl-6-formyl-1,3,2-dioxaborinan-4-yl) acetate: (general formula I)
（ａ）２０℃窒素雰囲気下でマグネシウム３．６５ｇ（０．１５モル）とＴＨＦ３６．０ｇ（０．３モル）を入れて２時間程度撹はんした後、ブロモメチルベンゼン１７．１ｇ（０．１モル）を徐々に滴加しながら６時間程度撹はんしてグリニャール試薬（Ｇｒｉｇｎａｒｄ ｒｅａｇｅｎｔ）を調製した。このグリニャール試薬を氷浴（ｉｃｅ ｂａｔｈ）で冷却した後、トリメトキシボラン（ｔｒｉｍｅｔｈｏｘｙｂｏｒａｎｅ）１０．４ｇ（０．１モル）を徐々に滴加しながら１時間程度撹はんの後に溶媒を除去し、ベンジルボロン酸（Ｂｅｎｚｙｌｂｏｒｏｎｉｃ ａｃｉｄ）１２．８ｇを得た。収率：９４．８％ (A) In a nitrogen atmosphere at 20.degree. C., 3.65 g (0.15 mol) of magnesium and 36.0 g (0.3 mol) of THF were added and stirred for about 2 hours, and then 17.1 g (0. 0.1 g) of bromomethylbenzene. 1 mol) was gradually added dropwise, and the mixture was stirred for about 6 hours to prepare a Grignard reagent. After cooling the Grignard reagent in an ice bath, 10.4 g (0.1 mol) of trimethoxyborane was gradually added dropwise and the solvent was removed after stirring for about 1 hour. 12.8 g of benzylboronic acid was obtained. Yield: 94.8%
（ｂ）（３Ｒ，５Ｓ）−ｔ−ブチル３，５−ジヒドロキシ−６−テトラヒドロピラニルオキシ−ヘキサノエート１６ｇ（０．０５モル）をトルエン５０ｍｌで希釈し、ベンジルボロン酸６．８ｇ（０．０５モル）を投入した後、１０時間還流させながら共沸蒸留を施して水を除去した。減圧下でトルエンを除去し、ジエチルエーテル５０ｍｌを入れて５℃以下に冷却させた後に沈殿物分離し、ｔ−ブチル２−（（４Ｒ，６Ｓ）−２−ベンジル−６−テトラヒドロピラニルオキシメチル−１，３，２−ジオキサボリナン−４−イル）アセテート１８．６ｇを得た。収率：９２％ (B) 16 g (0.05 mol) of (3R, 5S) -t-butyl 3,5-dihydroxy-6-tetrahydropyranyloxy-hexanoate was diluted with 50 ml of toluene, and 6.8 g (0.05 Mol) was added, and water was removed by azeotropic distillation while refluxing for 10 hours. Toluene was removed under reduced pressure, 50 ml of diethyl ether was added and the mixture was cooled to 5 ° C. or lower, and then the precipitate was separated to give t-butyl 2-((4R, 6S) -2-benzyl-6-tetrahydropyranyloxymethyl. 18.6 g of -1,3,2-dioxaborinan-4-yl) acetate was obtained. Yield: 92%
（ｃ）上記の得られたｔ−ブチル２−（（４Ｒ，６Ｓ）−２−ベンジル−６−テトラヒドロピラニルオキシメチル−１，３，２−ジオキサボリナン−４−イル）アセテート１８．６ｇに塩化メチレン（ＭＣ）６０ｍｌ、ＴＦＡ １５ｍｌを入れ、常温で８時間程度撹はんの後に有機層を乾燥させ、ｔ−ブチル２−（（４Ｒ，６Ｓ）−２−ベンジル−６−（ヒドロキシメチル）−１，３，２−ジオキサボリナン−４−イル）アセテート１４．２ｇを得た。 (C) The obtained t-butyl 2-((4R, 6S) -2-benzyl-6-tetrahydropyranyloxymethyl-1,3,2-dioxaborinan-4-yl) acetate was converted into 18.6 g of chloride. After adding 60 ml of methylene (MC) and 15 ml of TFA and stirring for about 8 hours at room temperature, the organic layer was dried and t-butyl 2-((4R, 6S) -2-benzyl-6- (hydroxymethyl)- 14.2 g of 1,3,2-dioxaborinan-4-yl) acetate was obtained.
（ｄ）塩化オキサリル（Ｏｘａｌｙｌ ｃｈｌｏｒｉｄｅ、１０ｍｌ）をＭＣに溶解させて−７８℃に保った後、ＤＭＳＯ（１３ｍｌ）を滴加して約１５分間撹はんした後、上記の得られたｔ−ブチル２−（（４Ｒ，６Ｓ）−２−ベンジル−６−（ヒドロキシメチル）−１，３，２−ジオキサボリナン−４−イル）アセテート１４．２ｇをＭＣに溶かした溶液を徐々に滴加して約１５分間撹はんした後、トリエチルアミン（３０ｍｌ）を滴加して１０分間撹はんした後、反応温度を室温に徐々に上げて反応させた。得られた有機層を水（１００ｍｌ）と食塩水（１００ｍｌ）で洗浄した後、無水硫酸マグネシウムで乾燥し濃縮して一般式Ｉの化合物１３．６ｇを得た。収率９５％ (D) Oxalyl chloride (Oxalyl chloride, 10 ml) was dissolved in MC and kept at −78 ° C. Then, DMSO (13 ml) was added dropwise and stirred for about 15 minutes, and then the above-obtained t- A solution of 14.2 g of butyl 2-((4R, 6S) -2-benzyl-6- (hydroxymethyl) -1,3,2-dioxaborinan-4-yl) acetate in MC was slowly added dropwise. After stirring for about 15 minutes, triethylamine (30 ml) was added dropwise and stirred for 10 minutes, and then the reaction temperature was gradually raised to room temperature for reaction. The obtained organic layer was washed with water (100 ml) and brine (100 ml), dried over anhydrous magnesium sulfate and concentrated to obtain 13.6 g of the compound of general formula I. Yield 95%
実施例２． ｔ−ブチル２−（（４Ｒ，６Ｓ）−２−ビフェニル−６−ホルミル−１，３，２−ジオキサボリナン−４−イル）アセテートの合成：（一般式II）Example 2 Synthesis of t-butyl 2-((4R, 6S) -2-biphenyl-6-formyl-1,3,2-dioxaborinan-4-yl) acetate: (general formula II)
上記実施例１で用いられたブロモメチルベンゼンに代えて４−ブロモメチルビフェニル２４．７ｇ（０．１モル）を出発物質とし、実施例１と同一の方法で一般式IIのボロネート化合物１８．８ｇを得た。収率：９１％ Instead of bromomethylbenzene used in Example 1, 24.7 g (0.1 mol) of 4-bromomethylbiphenyl was used as a starting material, and 18.8 g of boronate compound of the general formula II was prepared in the same manner as in Example 1. Got. Yield: 91%
［一般式II］ [General Formula II]
実施例３． ｔ−ブチル２−（（４Ｒ，６Ｓ）−２−（（ナフタリン−２−イル）メチル）−６−ホルミル−１，３，２−ジオキサボリナン−４−イル）アセテートの合成：（一般式III）Example 3 FIG. Synthesis of t-butyl 2-((4R, 6S) -2-((naphthalin-2-yl) methyl) -6-formyl-1,3,2-dioxaborin-4-yl) acetate: (general formula III)
上記実施例１で用いられたブロモメチルベンゼンに代えて２−ブロモメチルナフタリン２２．１ｇ（０．１モル）を出発物質とし、実施例１と同一の方法で一般式IIIのボロネート化合物１６．１ｇを得た。収率：８９％ In place of bromomethylbenzene used in Example 1 above, 22.1 g (0.1 mol) of 2-bromomethylnaphthalene was used as a starting material, and 16.1 g of boronate compound of the general formula III was prepared in the same manner as in Example 1. Got. Yield: 89%
［一般式III］ [General Formula III]
実施例４． ｔ−ブチル２−（（４Ｒ，６Ｓ）−２−（（アントラセン−２−イル）メチル）−６−ホルミル−１，３，２−ジオキサボリナン−４−イル）アセテートの合成：（一般式IV）Example 4 Synthesis of t-butyl 2-((4R, 6S) -2-((anthracen-2-yl) methyl) -6-formyl-1,3,2-dioxaborin-4-yl) acetate: (Formula IV)
上記実施例１で用いられたブロモメチルベンゼンに代えて２−ブロモメチルアントラセン［２−（ｂｒｏｍｏｍｅｔｈｙｌ）ａｎｔｈｒａｃｅｎｅ］２７．１ｇ（０．１モル）を出発物質とし、実施例１と同一の方法で一般式IVのボロネート化合物１８．３ｇを得た。収率：８６％ Instead of bromomethylbenzene used in Example 1 above, 2-bromomethylanthracene [2- (bromomethyl) anthracene] 27.1 g (0.1 mol) was used as a starting material, and the same method as in Example 1 was used. 18.3 g of boronate compound of formula IV was obtained. Yield: 86%
［一般式IV］ [General Formula IV]
実施例５． ｔ−ブチル２−（（４Ｒ，６Ｓ）−２−（（アントラセン−９−イル）メチル）−６−ホルミル−１，３，２−ジオキサボリナン−４−イル）アセテートの合成：（一般式V）Example 5 FIG. Synthesis of t-butyl 2-((4R, 6S) -2-((anthracen-9-yl) methyl) -6-formyl-1,3,2-dioxaborinan-4-yl) acetate: (general formula V)
上記実施例１で用いられたブロモメチルベンゼンに代えて９−ブロモメチルアントラセン［９−（ｂｒｏｍｏｍｅｔｈｙｌ）ａｎｔｈｒａｃｅｎｅ］２７．１ｇ（０．１モル）を出発物質とし、実施例１と同一の方法で一般式Vのボロネート化合物１７．８ｇを得た。収率：８４％ Instead of bromomethylbenzene used in Example 1 above, 27.1 g (0.1 mol) of 9-bromomethylanthracene [9- (bromomethyl) anthracene] was used as a starting material, and in the same manner as in Example 1 17.8 g of a boronate compound of formula V was obtained. Yield: 84%
［一般式V］ [General formula V]
実施例６． ｔ−ブチル２−（（４Ｒ，６Ｓ）−６−（（Ｅ）−２−（２−シクロプロピル−４−（４−フルオロフェニル）キノリン−３−イル）ビニル）−２−ベンジル−１，３−ジオキサン−４−イル）アセテートの製造：（一般式VI）Example 6 t-butyl 2-((4R, 6S) -6-((E) -2- (2-cyclopropyl-4- (4-fluorophenyl) quinolin-3-yl) vinyl) -2-benzyl-1, Preparation of 3-dioxan-4-yl) acetate: (general formula VI)
スタチンの母核として［２−シクロプロピル−４−（４−フルオロフェニル）キノリン−３−イル］メチルトリフェニル臭化ホスホニウム３０．８ｇ（０．０５モル）をＴＨＦ／アセトニトリル（２０／１の比率、１００ｍｌ）に溶かした後、温度を６０℃に上げた。反応溶液に水酸化リチウム水和物２．８ｇを入れ、実施例１で製造したｔ−ブチル２−（（４Ｒ，６Ｓ）−６−ホルミル−２−ベンジル−１，３−ジオキサン−４−イル）アセテート１６ｇ（０．０５モル）をＴＨＦ／アセトニトリル（１０／１の比率、５０ｍｌ）に溶かした溶液を滴加しながら３時間還流撹はんした後、室温に冷却させ、減圧し濃縮した。この濃縮液をヘプタン（３００ｍｌ）に溶かした後、０．１Ｎ ＨＣｌ（２００ｍｌ×２）と飽和食塩水（２００ｍｌ）で洗浄した。得られた有機層を無水硫酸マグネシウムで乾燥させた後に減圧濃縮した。得られた残渣を酢酸エチルとヘキサンを用いて再結晶し、固体状の下記一般式VIのピタバスタチン前駆体２６．２ｇを得た。（収率９１％、Ｅ／Ｚ＝９９／１） 30.8 g (0.05 mol) of [2-cyclopropyl-4- (4-fluorophenyl) quinolin-3-yl] methyltriphenylphosphonium bromide as a mother nucleus of statin in THF / acetonitrile (ratio of 20/1) , 100 ml), the temperature was raised to 60 ° C. 2.8 g of lithium hydroxide hydrate was added to the reaction solution, and t-butyl 2-((4R, 6S) -6-formyl-2-benzyl-1,3-dioxane-4-yl prepared in Example 1 was used. ) A solution prepared by dissolving 16 g (0.05 mol) of acetate in THF / acetonitrile (10/1 ratio, 50 ml) was stirred at reflux for 3 hours, and then cooled to room temperature, concentrated under reduced pressure. This concentrated solution was dissolved in heptane (300 ml) and then washed with 0.1N HCl (200 ml × 2) and saturated brine (200 ml). The obtained organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained residue was recrystallized using ethyl acetate and hexane to obtain 26.2 g of a solid pitavastatin precursor of the following general formula VI. (Yield 91%, E / Z = 99/1)
実施例７． ｔ−ブチル６−［（１Ｅ）−２−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］−５−ピリミジニル］エテニル］−２−ベンジル−１，３−ジオキサン−４−アセテートの製造：（一般式VII）Example 7 t-butyl 6-[(1E) -2- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] -5-pyrimidinyl] ethenyl] -2-benzyl-1, Production of 3-dioxane-4-acetate: (general formula VII)
上記実施例６と同一の方法で実施するが、スタチンの母核（芳香環）として［４−（４−フルオロフェニル）−６−イソプロピル−２−［（２−Ｎ−メチル−Ｎ−メチルスルホニル）アミノ］ピリミジン−５−イル］メチルトリフェニル臭化ホスホニウム３３．８ｇ（０．０５モル）を用いて下記一般式VIIのロスバスタチン前駆体２７．４ｇを得た。収率８６％、Ｅ／Ｚ＝９９／１ The same method as in Example 6 above, except that [4- (4-fluorophenyl) -6-isopropyl-2-[(2-N-methyl-N-methylsulfonyl) is used as the statin nucleus (aromatic ring). ) Amino] pyrimidin-5-yl] methyltriphenyl Phosphonium bromide (33.8 g, 0.05 mol) was used to obtain 27.4 g of a rosuvastatin precursor of the following general formula VII. Yield 86%, E / Z = 99/1
［一般式VII］ [General Formula VII]
実施例８． ｔ−ブチル２−（（４Ｒ，６Ｓ）−２−ベンジル−６−（（Ｅ）−２−（６−（ジメチルアミノ）−４−（４−フルオロフェニル）−２−イソプロピル−５−（メトキシメチル）ピリジン−３−イル）ビニル）−１，３，２−ジオキサボリナン−４−イル）アセテートの製造：（一般式VIII）Example 8 FIG. t-Butyl 2-((4R, 6S) -2-benzyl-6-((E) -2- (6- (dimethylamino) -4- (4-fluorophenyl) -2-isopropyl-5- (methoxy) Preparation of methyl) pyridin-3-yl) vinyl) -1,3,2-dioxaborin-4-yl) acetate: (general formula VIII)
上記実施例６と同一の方法で実施するが、スタチンの母核（芳香環）として［４−（４−フルオロフェニル）−６−イソプロピル−２−［ジメチルアミノ］ピリミジン−５−イル］メチルトリフェニル臭化ホスホニウム３２．８ｇ（０．０５モル）を用いて下記一般式VIIIのセリバスタチン前駆体２７．７ｇを得た。収率９０％、Ｅ／Ｚ＝９９／１ The same method as in Example 6 above, but with [4- (4-fluorophenyl) -6-isopropyl-2- [dimethylamino] pyrimidin-5-yl] methyltrimethyl as the statin nucleus (aromatic ring) Using 22.8 g (0.05 mol) of phosphonium phenyl bromide, 27.7 g of a cerivastatin precursor of the following general formula VIII was obtained. Yield 90%, E / Z = 99/1
［一般式VIII］ [General Formula VIII]
実施例９． ｔ−ブチル２−（（４Ｒ，６Ｓ）−２−ベンジル−６−（（Ｅ）−２−（３−（４−フルオロフェニル）−１−イソプロピル−１Ｈ−インドール−２−イル）ビニル）−１，３，２−ジオキサボリナン−４−イル）アセテートの製造：（一般式IX）Example 9 t-Butyl 2-((4R, 6S) -2-benzyl-6-((E) -2- (3- (4-fluorophenyl) -1-isopropyl-1H-indol-2-yl) vinyl)- Preparation of 1,3,2-dioxaborinan-4-yl) acetate: (general formula IX)
上記実施例６と同一の方法で実施するが、スタチンの母核（芳香環）として［３−（４−フルオロフェニル）−１−イソプロピル−１Ｈ−インドール−２−イル］メチルトリフェニル臭化ホスホニウム３０．４ｇ（０．０５モル）を用いて下記一般式IXのフルバスタチン前駆体２４．７ｇを得た。収率８７％、Ｅ／Ｚ＝９９／１ Performed in the same manner as in Example 6 but with [3- (4-fluorophenyl) -1-isopropyl-1H-indol-2-yl] methyltriphenylphosphonium bromide as the statin nucleus (aromatic ring) Using 30.4 g (0.05 mol), 24.7 g of a fluvastatin precursor of the following general formula IX was obtained. Yield 87%, E / Z = 99/1
［一般式IX］ [General formula IX]
実施例１０． ｔ−ブチル−ピタバスタチンの製造Example 10 Production of t-butyl-pitavastatin
実施例６で製造されたｔ−ブチル２−（（４Ｒ，６Ｓ）−６−（（Ｅ）−２−（２−シクロプロピル−４−（４−フルオロフェニル）キノリン−３−イル）ビニル）−２−ベンジル−１，３−ジオキサン−４−イル）アセテート２６．２ｇをエタノール（５０ｍｌ）に溶かした後、１Ｎ水酸化ナトリウム水溶液（１００ｍｌ）を滴加して２時間撹はんした後、水（１００ｍｌ）を添加し、ジエチルエーテル（１００ｍｌ×２）で抽出した。有機層を捨て、水層を濃い塩酸にてｐＨ１．０とし、約１時間撹はんした。その後、クロロホルム（１００ｍｌ×２）で抽出し、無水硫酸マグネシウムで乾燥させた後に減圧、濃縮してｔ−ブチル−ピタバスタチン２０．６ｇを得た。収率９５％ T-Butyl 2-((4R, 6S) -6-((E) -2- (2-cyclopropyl-4- (4-fluorophenyl) quinolin-3-yl) vinyl) prepared in Example 6) 2-Benzyl-1,3-dioxan-4-yl) acetate (26.2 g) was dissolved in ethanol (50 ml), 1N aqueous sodium hydroxide solution (100 ml) was added dropwise, and the mixture was stirred for 2 hours. Water (100 ml) was added and extracted with diethyl ether (100 ml × 2). The organic layer was discarded, and the aqueous layer was adjusted to pH 1.0 with concentrated hydrochloric acid and stirred for about 1 hour. Thereafter, the mixture was extracted with chloroform (100 ml × 2), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain 20.6 g of t-butyl-pitavastatin. Yield 95%
本発明は、スタチン（ｓｔａｔｉｎ）類の合成に用いられる新規な中間体及びその製造方法、並びに上記スタチン類中間体を用いてピタバスタチン、ロスバスタチン、セリバスタチン、フルバスタチンを製造する方法に関する。 The present invention relates to a novel intermediate used for the synthesis of statins and a method for producing the same, and a method for producing pitavastatin, rosuvastatin, cerivastatin and fluvastatin using the above-mentioned statins intermediate.
Claims (8)
[一般式１]
Ｒ １ 、Ｒ ２ 、Ｒ ３ はそれぞれ独立して、Ｈ、Ｃ １ 〜Ｃ ４ のアルキルであり、Ｒ ４ はＣ １ 〜Ｃ ８ のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルである。） A statin intermediate, which is a compound represented by the following general formula 1.
[General formula 1]
R 1 , R 2 , R 3 are each independently H, C 1 -C 4 alkyl, and R 4 is C 1 -C 8 alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl. . )
（ｂ）下記一般式５のアラルキルボロン酸を下記一般式４で表されるアセテート化合物と反応させて下記一般式３のボロネートエステル化合物を合成する段階と、 (B) reacting an aralkylboronic acid of the following general formula 5 with an acetate compound represented by the following general formula 4 to synthesize a boronate ester compound of the following general formula 3,
（ｃ）下記一般式３のボロネートエステル化合物を弱い酸触媒を用いて脱保護して下記一般式２の化合物を生成する段階と、 (C) deprotecting a boronate ester compound of the following general formula 3 using a weak acid catalyst to produce a compound of the following general formula 2:
（ｄ）下記一般式２の化合物を塩化オキサリル又はクロロクロム酸ピリジニウムを用いて酸化させる段階と、 (D) oxidizing a compound of the following general formula 2 with oxalyl chloride or pyridinium chlorochromate;
を含む、一般式１で表されるスタチン中間体の製造方法。A method for producing a statin intermediate represented by the general formula 1, comprising:
［反応式１］[Reaction Formula 1]
Ｘは、Ｂｒ、Ｃｌ又はＩであり、X is Br, Cl or I;
ＲR １1 、Ｒ, R ２2 、Ｒ, R ３3 はそれぞれ独立して、Ｈ、ＣAre independently H, C １1 〜Ｃ~ C ４4 のアルキルであり、The alkyl of
ＲR ４4 は、ＣIs C １1 〜Ｃ~ C ８8 のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルであり、Alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl,
ＲR ５5 は、テトラヒドロピラニル、ｔ−ブチルジメチルシリル又はトリチルである。）Is tetrahydropyranyl, t-butyldimethylsilyl or trityl. )
［一般式７］[General Formula 7]
ＲR １1 、Ｒ, R ２2 、Ｒ, R ３3 はそれぞれ独立して、Ｈ、ＣAre independently H, C １1 〜Ｃ~ C ４4 のアルキルであり、ＲOf alkyl and R ４4 はＣIs C １1 〜Ｃ~ C ８8 のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルである。）Alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl. )
［一般式８］[General Formula 8]
ＲR １1 、Ｒ, R ２2 、Ｒ, R ３3 はそれぞれ独立して、Ｈ、ＣAre independently H, C １1 〜Ｃ~ C ４4 のアルキルであり、ＲOf alkyl and R ４4 はＣIs C １1 〜Ｃ~ C ８8 のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルである。）Alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl. )
［一般式９］[General formula 9]
ＲR １1 、Ｒ, R ２2 、Ｒ, R ３3 はそれぞれ独立して、Ｈ、ＣAre independently H, C １1 〜Ｃ~ C ４4 のアルキルであり、ＲOf alkyl and R ４4 はＣIs C １1 〜Ｃ~ C ８8 のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルである。）Alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl. )
［一般式１０］[General formula 10]
ＲR １1 、Ｒ, R ２2 、Ｒ, R ３3 はそれぞれ独立して、Ｈ、ＣAre independently H, C １1 〜Ｃ~ C ４4 のアルキルであり、ＲOf alkyl and R ４4 はＣIs C １1 〜Ｃ~ C ８8 のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルである。）Alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl. )
［一般式１−１］[General Formula 1-1]
ＲR １1 、Ｒ, R ２2 、Ｒ, R ３3 はそれぞれ独立して、Ｈ、ＣAre independently H, C １1 〜Ｃ~ C ４4 のアルキルであり、ＲOf alkyl and R ４4 はＣIs C １1 〜Ｃ~ C ８8 のアルキル、２級アルキル、３級アルキル、アリール又はアラルキルである。）Alkyl, secondary alkyl, tertiary alkyl, aryl or aralkyl. )
［一般式７ａ］[General Formula 7a]
［一般式８ａ］[General Formula 8a]
［一般式９ａ］[General Formula 9a]
［一般式１０ａ］[General Formula 10a]
Ｙは、ＰＰｈY is PPh ３3 ＋+ ＸX −− （Ｘ＝ハライド）又はＰ(Ｏ)(ＯＥｔ)(X = halide) or P (O) (OEt) ２2 である。）It is. )
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120052296A KR101292743B1 (en) | 2012-05-17 | 2012-05-17 | Novel statins intermediates and method for synthesizing pitavastain, rosuvastatin, cerivastatin and fluvastatin by using statins intermediates |
| KR10-2012-0052296 | 2012-05-17 | ||
| PCT/KR2013/004380 WO2013172687A1 (en) | 2012-05-17 | 2013-05-16 | Novel statin intermediate, and production method for pitavastatin, rosuvastatin, cerivastatin and fluvastatin using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015513556A JP2015513556A (en) | 2015-05-14 |
| JP6034888B2 true JP6034888B2 (en) | 2016-11-30 |
Family
ID=49219769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560870A Active JP6034888B2 (en) | 2012-05-17 | 2013-05-16 | Novel statin intermediate and method for producing pitavastatin, rosuvastatin, cerivastatin and fluvastatin using the same |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6034888B2 (en) |
| KR (1) | KR101292743B1 (en) |
| WO (1) | WO2013172687A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101528359B1 (en) * | 2013-04-24 | 2015-06-15 | (주) 성운파마코피아 | Novel boronate ether intermediates for preparation of statin compounds, preparation method thereof and preparation method of statin compounds using said boronate ether intermediates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3741509A1 (en) * | 1987-12-08 | 1989-06-22 | Hoechst Ag | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-DESMETHYLMEVALONIC ACID DERIVATIVES AND INTERMEDIATE PRODUCTS |
| GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
| KR100849880B1 (en) * | 2001-12-20 | 2008-08-01 | 주식회사 중외제약 | New process for the preparation of optically active 2-[6-substituted alkyl-1,3-dioxan-4-yl]acetic acid derivatives |
| ES2332881T3 (en) * | 2002-02-25 | 2010-02-15 | Biocon Limited | NEW ESTERES OF BORANATO. |
| WO2004113314A1 (en) * | 2003-06-23 | 2004-12-29 | Biocon Limited | Novel boronate esters |
| KR100881617B1 (en) * | 2007-02-22 | 2009-02-17 | (주) 성운파마코피아 | Atorvastatin intermediates and method for producing the same |
| FR2938538B1 (en) * | 2008-11-17 | 2011-08-05 | Univ Nice Sophia Antipolis | PROCESS FOR THE PREPARATION OF ACIDS AND BORONIC ESTERS IN THE PRESENCE OF METAL MAGNESIUM |
| KR101164426B1 (en) | 2010-04-14 | 2012-07-12 | (주)부흥산업사 | Precursor, intermediates and their salts of statin series for hyperlipemia and manufacturing method for them |
| KR100995882B1 (en) * | 2010-06-08 | 2010-11-22 | 에이치 엘 지노믹스(주) | Process for preparing intermediate of pitavastatin or its salt |
-
2012
- 2012-05-17 KR KR1020120052296A patent/KR101292743B1/en active IP Right Grant
-
2013
- 2013-05-16 WO PCT/KR2013/004380 patent/WO2013172687A1/en active Application Filing
- 2013-05-16 JP JP2014560870A patent/JP6034888B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015513556A (en) | 2015-05-14 |
| WO2013172687A1 (en) | 2013-11-21 |
| KR101292743B1 (en) | 2013-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5146965B2 (en) | Method for preparing amorphous rosuvastatin calcium free of impurities | |
| EP1737829A2 (en) | Preparation of rosuvastatin | |
| JP2009500388A (en) | Rosuvastatin and intermediate production method | |
| EP1902036B1 (en) | Process for the preparation of rosuvastatin and intermediates | |
| US7812179B2 (en) | Process for the preparation of atorvastatin and intermediates | |
| JP2013516459A (en) | Process for the production of pitavastatin and pharmaceutically acceptable salts thereof | |
| JP5558492B2 (en) | Major intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof | |
| KR20130087153A (en) | Method for preparing rosuvastatin and intermediate compound used therefor | |
| JP6034888B2 (en) | Novel statin intermediate and method for producing pitavastatin, rosuvastatin, cerivastatin and fluvastatin using the same | |
| KR101063146B1 (en) | Method for preparing pitavastatin intermediate and method for preparing pitavastatin hemicalcium salt | |
| WO2008077305A1 (en) | Quinoline compounds, intermediates, prepartion methods and uses thereof | |
| WO2009143776A1 (en) | Preparation method of rosuvastatin calcium and its intermediates | |
| WO2009024323A2 (en) | Process for preparing pyrimidine derivatives | |
| KR20140017207A (en) | Rosuvastatin isopropyl amine salt, the preparation method thereof and the preparation method of rosuvastatin hemicalcium salt using the same | |
| KR20120125190A (en) | Process for the preparation of t-butyl 2-4R,6S-6-formyl-2,2-dimethyl-1,3-dioxane-4-ylacetate | |
| JP2013544258A (en) | Preparation of rosuvastatin salt | |
| WO2015131405A1 (en) | Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom | |
| JP5796836B2 (en) | Process for producing intermediate of pitavastatin or a salt thereof | |
| KR101528359B1 (en) | Novel boronate ether intermediates for preparation of statin compounds, preparation method thereof and preparation method of statin compounds using said boronate ether intermediates | |
| JP6231262B2 (en) | Method for producing a precursor of pitavastatin calcium | |
| CN108822090B (en) | Preparation method of statin drug intermediate | |
| KR101134021B1 (en) | Manufacturing method of pitavastatin hemicalcium using novel intermediates | |
| JP2012506367A (en) | Crystalline Montelukast salt | |
| JP2021526142A (en) | Process for preparing 2- (1- (tert-butoxycarbonyl) piperidine-4-yl) benzoic acid | |
| KR101566536B1 (en) | Process for the preparation of (E)-tert-butyl-2-(6-(2-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl,methylsulfonamido)pyrimidin-5-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate as a rosuvastatine intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150805 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151104 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160203 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160229 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160519 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160826 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161024 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161028 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6034888 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D03 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |